Harbinger Health announced a $100 million Series B financing to support commercialization plans for its Resolve blood-based multi-cancer detection tests. The company said the funding will back the Resolve portfolio launch effort, advancement of its Harbinger HX platform, and continuation of the PROCARES prospective validation study. Harbinger noted that more than 88% of PROCARES enrollment is complete. Resolve is designed to reduce false negatives and false positives in identifying cancer suspicion and to provide actionable information on potential tissue of origin, backed by AI-driven analysis of cancer biology.